Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Rises By 19.8%

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 7,680,000 shares, a growth of 19.8% from the December 15th total of 6,410,000 shares. Currently, 16.4% of the shares of the company are short sold. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 7.3 days.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares in the company, valued at $15,101,171.16. The trade was a 8.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 108,334 shares of company stock worth $6,070,020. 29.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of large investors have recently bought and sold shares of the business. Avanza Fonder AB purchased a new position in Janux Therapeutics during the 4th quarter worth $139,000. Franklin Resources Inc. grew its stake in shares of Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock worth $937,000 after acquiring an additional 7,442 shares during the last quarter. Virtu Financial LLC increased its holdings in shares of Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after acquiring an additional 2,419 shares in the last quarter. Neo Ivy Capital Management purchased a new position in shares of Janux Therapeutics in the 3rd quarter valued at approximately $940,000. Finally, Geode Capital Management LLC boosted its stake in Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after purchasing an additional 38,490 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Analyst Ratings Changes

JANX has been the topic of several analyst reports. HC Wainwright increased their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. UBS Group initiated coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $69.00 price objective on the stock. BTIG Research upped their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Finally, Scotiabank upped their target price on Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a report on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $89.90.

Janux Therapeutics Stock Performance

Shares of JANX stock traded up $0.11 during trading hours on Monday, reaching $40.72. The company had a trading volume of 802,219 shares, compared to its average volume of 815,856. The firm has a market cap of $2.14 billion, a PE ratio of -34.80 and a beta of 3.23. The business has a fifty day moving average price of $52.83 and a 200-day moving average price of $48.42. Janux Therapeutics has a one year low of $7.79 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics's revenue was down 82.6% compared to the same quarter last year. Equities research analysts forecast that Janux Therapeutics will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.